Anguidine: a broad phase II study of the Southeastern Cancer Study Group.
作者信息
Adler S S, Lowenbraun S, Birch B, Jarrell R, Garrard J
出版信息
Cancer Treat Rep. 1984 Feb;68(2):423-5.
PMID:6697331
Abstract
Anguidine, a phase II agent, was used to treat 276 patients with solid tumors. The overall evaluability rate was 68%. Hematologic toxicity was substantial but not prohibitive. There were no complete responses, two partial responses, and 12 stabilizations.
摘要
Zotero 插件